Home > Market Activity > Get Quotes > News > News Article

Abattis Bioceuticals Corp

Exchange: Canadian Securities Exchange (CNSX) | Sep 18, 2018, 11:46 PM EDT

ATT:CNX
$ 0.185 No Change
Change:
0.00 (0.00%)
Volume:
1,611,542

Day Low 0.175
Day High 0.185


 Back
,
Abattis awarded a Mitacs grant for R&D of nanoemulsified cannabinoid-rich hemp oil in conjunction with food scientists from the University of British Columbia

VANCOUVER, British Columbia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce the sponsorship of a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work will be led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia (“UBC”).

Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 18 years working with 60 universities, thousands of companies, and both federal and provincial governments.

In addition to the R&D work on cannabinoid-rich THC-free hemp extracts, scientist from Abattis and UBC’s Faculty of Land and Food Systems will work to create delivery platforms with increased stability and bioavailability.

“Abattis is very pleased to begin working with premiere scientists from UBC, and in the University’s first-class cell-culture research facility,” said Rob Abenante, President and CEO of Abattis.

Mr. Abenante added: “Our partnership will focus on developing nanoparticle-based delivery platforms since nanoparticulation allow more efficient and faster absorption of active compounds such as cannabinoids and terpenes, reducing the typical losses associated with gut absorption. This new development is part of our overall strategy to provide high-end extracts to our manufacturing partners and to support the development of unique finished products.”

"Our research will help develop stable encapsulated hemp-oil formulations for delivering the medicinal ingredients of cannabis orally, but without the harmful effects of smoking. Stable hemp extracts, with tailored profiles of cannabinoids and terpenes, could be used for targeted treatment of patients and help them lead a healthy lifestyle," said Dr. Anubhav Pratap Singh, Assistant Professor, Food Nutrition and Health Program, Faculty of Land and Food Systems, UBC.

The University of British Columbia’s Faculty of Land and Food Systems has world-class research laboratories with modern analytical instrumentation. UBC consistently ranks among the Top 40 universities in the world, and among the Top 20 public universities in the world.

"Securing this partnership provides additional support to our Research and Development strategy to prepare a new class of cannabis and hemp finished products with high bioavailability, stability and shelf-life. This technology will become a core driver for a future line of formulations to be used under white-label, and in-house finished products," said Dr. David Galvez, Senior Science Advisor of Abattis. 

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

“Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com. 

FORWARD LOOKING INFORMATION 

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the research and development to be performed between the Company and UBC; the success of its formulation efforts on proprietary cannabinoid oils; the success of the marketing and sales of its proprietary formulations; the bioavailability and product efficacy of the results of the research conducted.   Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including that the partnership with UBC or the grant will result in useful product developments.  Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

Primary Logo

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.